Development
Cullinan Therapeutics, Inc.
CGEM
$8.08
$0.141.76%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.94% | 8.88% | 13.55% | 31.26% | -1.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.43% | 50.52% | 6.21% | 92.17% | 0.76% |
| Operating Income | -31.43% | -50.52% | -6.21% | -92.17% | -0.76% |
| Income Before Tax | -37.10% | -42.94% | -113.41% | -79.12% | 15.38% |
| Income Tax Expenses | -660.06% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.63% | -57.42% | -118.51% | -350.99% | 20.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 475.16% | -- | -- | -77.46% | -81.91% |
| Net Income | 11.12% | -57.97% | -118.42% | -379.10% | 17.63% |
| EBIT | -31.43% | -50.52% | -6.21% | -92.17% | -0.76% |
| EBITDA | -31.43% | -50.29% | -6.02% | -92.02% | -0.62% |
| EPS Basic | 4.99% | -68.61% | -120.69% | -423.25% | 21.42% |
| Normalized Basic EPS | -29.42% | -51.58% | -7.62% | -102.60% | 7.76% |
| EPS Diluted | 5.31% | -68.61% | -121.75% | -423.25% | 21.38% |
| Normalized Diluted EPS | -29.42% | -51.58% | -11.24% | -102.60% | 7.76% |
| Average Basic Shares Outstanding | -6.46% | -6.31% | -10.97% | -8.44% | 4.83% |
| Average Diluted Shares Outstanding | -6.46% | -6.31% | -13.86% | -8.44% | 4.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |